Generic Name and Formulations:
Midodrine HCl 2.5mg, 5mg, 10mg; scored tabs.
Various generic manufacturers
Indications for Midodrine:
Symptomatic orthostatic hypotension.
Take during the day while upright; allow at least 4 hours between last dose and bedtime. 10mg 3 times daily at 3–4 hour intervals. Renal dysfunction: initially 2.5mg 3 times daily. Discontinue if no improvement after initial therapy.
Severe heart disease. Acute renal disease. Urinary retention. Pheochromocytoma. Thyrotoxicosis. Persistent, excessive supine hypertension.
Initial supine systolic pressure >180mmHg: not recommended. Monitor supine and sitting BP. Discontinue if supine hypertension occurs. Diabetes. Renal or hepatic impairment. Pregnancy (Cat.C). Nursing mothers.
Avoid concomitant drugs that increase BP (eg, phenylephrine, pseudoephedrine, ephedrine, dihydroergotamine, thyroid hormones, droxidopa); if unavoidable, monitor BP closely. Avoid concomitant MAO inhibitors or linezolid. Potentiated by sodium-retaining steroids (eg, fludrocortisone acetate); caution in increased intraocular pressure with fludrocortisone. Antagonized by α-antagonists (eg, prazosin, terazosin, doxazosin). Levels may be affected by renally-excreted alkaline drugs (eg, metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, quinidine). Cardiac glycosides, β-blockers, CNS drugs may cause bradycardia, AV block, arrhythmias; discontinue if bradycardia occurs.
Paresthesia, piloerection, dysuria, pruritus, supine hypertension, chills, pain, rash.
Formerly known under the brand name Proamatine.
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness